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Coronavirus Disease 2019 (COVID-19)
Strategies for Optimizing the Supply of N95
Respirators: Crisis/Alternate Strategies
Crisis/Alternate Strategies
These crisis capacity or alternate strategies accompany and build on the conventional and contingency capacity
strategies. The following measures are not commensurate with current U.S. standards of care. However, individual
measures or a combination of these measures may need to be considered during periods of expected or known N95
respirator shortages. It is important to consult with entities that include some combination of: local healthcare coalitions,
federal, state, or local public health officials, appropriate state agencies that are managing the overall emergency
response related to COVID-19, and state crisis standards of care committees. Even when state/local healthcare coalitions
or public health authorities can shift resources between health care facilities, these strategies may still be necessary.
When N95 Supplies are Running Low
Personal Protective Equipment and Respiratory Protection
Use of respirators beyond the manufacturer-designated shelf life for healthcare delivery
Consideration can be made to use N95 respirators beyond the manufacturer-designated shelf life for care of patients
with COVID-19, tuberculosis, measles, and varicella. However, respirators beyond the manufacturer-designated shelf life
may not perform to the requirements for which they were certified. Over time, components such as the straps and nose
bridge material may degrade, which can affect the quality of the fit and seal. Many models found in U.S. stockpiles and
stockpiles of healthcare facilities have been found to continue to perform in accordance with NIOSH performance
standards. However, fluid resistance and flammability were not assessed. Use of the N95 respirators recommended in
Release of Stockpiled N95 Filtering Facepiece Respirators Beyond the Manufacturer-Designated Shelf Life: Considerations
for the COVID-19 Response can be considered. It is optimal to use these respirators in the context of a respiratory
protection program that includes medical evaluation, training, and fit testing. If used in healthcare delivery, it is
particularly important that HCP perform the expected seal check, prior to entering a patient care area. CDC does not
recommend using N95s beyond the manufacturer-designated shelf life in surgical settings.
Use of respirators approved under standards used in other countries that are similar to NIOSH-
approved N95 respirators
Other countries approve respirators for occupational use and approve respirators to these standards. These products are
evaluated using some methods similar to those used by NIOSH, and some methods that are different, but are expected
to protect HCPs. These respirators are expected to provide protection to workers. Those with equivalent or similar
protection to NIOSH-approved respirators may be available to provide respiratory protection to workers exposed to
harmful airborne particulate matter. These devices are expected to be suitable alternatives to provide protection during
the COVID-19 response when supplies are short. The country, conformity assessment standards, acceptable product
classifications, standards and guidance documents, and protection factor determination are provided in alphabetical
order. All of these respirators have protection factors of at least 10 in the countries listed below, as outlined in the
standards and guidance documents specified.
Country
Performance
Standard
Acceptable product
classifications
Standards/Guidance
Documents
Protection
Factor ≥ 10
Australia AS/NZS
1716:2012
P3
P2
AS/NZS 1715:2009 YES
Brazil ABNT/NBR
13698:2011
PFF3
PFF2
Fundacentro CDU
614.894
YES
China GB 2626-2006 KN 100 KP100
KN95 KP95
GB/T 18664—2002 YES
Europe EN 149-2001 FFP3
FFP2
EN 529:2005 YES
Japan JMHLW-2000 DS/DL3
DS/DL2
JIS T8150: 2006 YES
Korea KMOEL-2017-64 Special
1st
KOSHA GUIDE H-82-2015 YES
Mexico NOM-116-2009 N100, P100, R100
N99, P99, R99
N95, P95, R95
NOM-116 YES
US NIOSH
Requirements
NIOSH
approved
42 CFR 84
N100, P100, R100
N99, P99, R99
N95, P95, R95
OSHA 29CFR1910.134 YES
Limited re-use of N95 respirators for COVID-19 patients
Limited re-use of N95 respirators when caring for patients with COVID-19 might become necessary. However, it is
unknown what the potential contribution of contact transmission is for SARS-CoV-2, and caution should be used. Re-use
should be implemented according to CDC guidance. Re-use has been recommended as an option for conserving
respirators during previous respiratory pathogen outbreaks and pandemics. It may also be necessary to re-use N95
respirators when caring for patients with varicella or measles, although contact transmission poses a risk to HCP who
implement this practice.
Use of additional respirators beyond the manufacturer-designated shelf life for healthcare delivery
Use of additional N95 respirators beyond the manufacturer-designated shelf life for care of patients with COVID-19,
tuberculosis, measles, and varicella can be considered. However, respirators beyond the manufacturer-designated shelf
life may not perform to the requirements for which they were certified. Over time, components such as the straps and
nose bridge material may degrade, which can affect the quality of the fit and seal. Some models have been found NOT to
perform in accordance with NIOSH performances standards, and consideration may be given to use these respirators as
identified in Release of Stockpiled N95 Filtering Facepiece Respirators Beyond the Manufacturer-Designated Shelf Life:
Considerations for the COVID-19 Response. In addition, consideration can be given to use N95 respirators beyond the
manufacturer-designated shelf life that have not been evaluated by NIOSH. It is optimal to use these respirators in the
context of a respiratory protection program that includes medical evaluation, training, and fit testing. It is particularly
important that HCP perform the expected seal check, prior to entering a patient care area.
Prioritize the use of N95 respirators and facemasks by activity type
The number of infectious particles required to cause an infection (infectious dose) is often uncertain or unknown for
respiratory pathogens. Further, there is often uncertainty about the influence of factors such as exposure duration and
nature of clinical symptoms on the likelihood of infection transmission from person-to-person. When facemasks must be
used by HCP entering a patient care area, source control (i.e. masking of symptomatic patients) and maintaining distance
from the patient are particularly important to reduce the risk of transmission.
This prioritization approach to conservation is intended to be used when N95 respirators are so limited that routinely
practiced standards of care for all HCP wearing N95 respirators when caring for a COVID-19 patient are no longer
possible. N95 respirators beyond their manufacture-designated shelf life, when available, are preferable to use of
facemasks. The use of N95s or elastomeric respirators or PAPRs should be prioritized for HCP with the highest potential
exposures including being present in the room during aerosol generating procedures performed on symptomatic
persons.
Suggested facemask or respirator use, based upon distance from a patient with suspected or known COVID-19 and use of
source control*
HCP planned proximity to
the case patient during
encounter
Facemask or respirator determination
Patient masked for entire
encounter (i.e., with source control)
Unmasked patient or mask needs
to be removed for any period of
time during the patient encounter
HCP will remain at greater
than 6 feet from symptomatic
patient
HCP remaining at this distance from the
patient should not need to enter the
patient care area; if entry required: no
facemask or respirator
HCP remaining at this distance from the
patient should not need to enter the
patient care area; if entry required: no
facemask or respirator
HCP will be within 3 to 6 feet
of symptomatic patient
HCP remaining at this distance from the
patient should not need to enter the
patient care area; if entry required:
facemask
HCP remaining at this distance from the
patient should not need to enter the
patient care area; if entry required:
facemask
HCP will be within 3 feet of
symptomatic patient,
including providing direct
Facemask N95 respirator/ elastomeric /PAPR,
based on availability
patient care
HCP will be present in the
room during aerosol
generating procedures
performed on symptomatic
persons
N95 respirator/ elastomeric /PAPR,
based on availability
N95 respirator/ elastomeric /PAPR,
based on availability
Show More
*Based on availability, organizations may require and/or individuals may voluntarily choose to utilize higher levels of protection
When No Respirators are Left
Administrative Controls
Exclude HCP at higher risk for severe illness from COVID-19 from contact with known or suspected
COVID-19 patients
During severe resource limitations, consider excluding HCP who may be at higher risk for severe illness from COVID-19,
such as those of older age, those with chronic medical conditions, or those who may be pregnant, from caring for
patients with confirmed or suspected COVID-19 infection.
Designate convalescent HCP for provision of care to known or suspected COVID-19 patients
It may be possible to designate HCP who have clinically recovered from COVID-19 to preferentially provide care for
additional patients with COVID-19. Individuals who have recovered from COVID-19 infection may have developed some
protective immunity, but this has not yet been confirmed.
Engineering Controls
Expedient patient isolation rooms for risk-reduction
Portable fan devices with high-efficiency particulate air (HEPA) filtration that are carefully placed can increase the effective
air changes per hour of clean air to the patient room, reducing risk to individuals entering the room without respiratory
protection. NIOSH has developed guidance for using portable HEPA filtration systems to create expedient patient
isolation rooms. The expedient patient isolation room approach involves establishing a high-ventilation-rate, negative
pressure, inner isolation zone that sits within a “clean” larger ventilated zone. In the absence of any remaining supply of
N95 respirators, it may be possible to use this technology in conjunction with HCP wearing facemasks.
Ventilated Headboards
NIOSH has developed the ventilated headboard that draws exhaled air from a patient in bed into a HEPA filter,
decreasing risk of HCP exposure to patient-generated aerosol. This technology consists of lightweight, sturdy, and
adjustable aluminum framing with a retractable plastic canopy. The ventilated headboard can be deployed in
combination with HEPA fan/filter units to provide surge isolation capacity within a variety of environments, from
traditional patient rooms to triage stations, and emergency medical shelters. In the absence of any remaining supply of
N95 respirators, it may be possible to use this technology in conjunction with HCP and/or patients wearing facemasks.
Personal Protective Equipment and Respiratory Protection
HCP use of non-NIOSH approved masks or homemade masks
In settings where N95 respirators are so limited that routinely practiced standards of care for wearing N95 respirators
and equivalent or higher level of protection respirators are no longer possible, and surgical masks are not available, as a
last resort, it may be necessary for HCP to use masks that have never been evaluated or approved by NIOSH or
homemade masks. It may be considered to use these masks for care of patients with COVID-19, tuberculosis, measles,
and varicella. However, caution should be exercised when considering this option.1,2
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